Clinical Trial Detail

NCT ID NCT02436993
Title Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of California, Irvine
Indications

breast carcinoma

Therapies

Bevacizumab

Pertuzumab + Trastuzumab

Carboplatin + Paclitaxel

Age Groups: adult

No variant requirements are available.